~ Buy the OLUMIANT (baricitinib) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR OLUMIANT

All Clinical Trials for Olumiant

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03921554 ↗	JAK Inhibitor Treatment in AGS	Active, not recruiting	Eli Lilly and Company	Phase 2	2019-06-03	The primary objective of this study is to assess safety as well as efficacy of baricitinib, a Janus Kinase (JAK) inhibitor, in patients with Aicardi Goutières Syndrome (AGS), a multisystem heritable disorder of the innate immunity resulting in excessive interferon production
NCT03921554 ↗	JAK Inhibitor Treatment in AGS	Active, not recruiting	Adeline Vanderver, MD	Phase 2	2019-06-03	The primary objective of this study is to assess safety as well as efficacy of baricitinib, a Janus Kinase (JAK) inhibitor, in patients with Aicardi Goutières Syndrome (AGS), a multisystem heritable disorder of the innate immunity resulting in excessive interferon production
NCT04131738 ↗	Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation	Recruiting	Washington University School of Medicine	Phase 1	2020-04-07	In this trial, the investigators will begin to explore the possibility that, as in mice, JAK1/2 inhibition with hematopoietic cell transplantation (HCT) may mitigate graft-versus-host-disease (GVHD) while retaining engraftment and Graft-versus-Leukemia (GVL). Both preclinical and clinical data suggest that inhibition of IFNy and IL-6, directly and using downstream JAK Inhibitors, may be an effective strategy to decrease toxicities and improve disease control for patients undergoing Allogeneic HSCT. Baricitinib, as a JAK1/2 inhibitor, has shown superiority to other JAK inhibitors in preclinical GVHD models. The purpose of this phase I clinical trial is to determine the safety of baricitinib with HSCT measured by the effect on engraftment and grade III-IV acute graft-versus-host-disease (aGVHD).

Clinical Trial Conditions for Olumiant

Condition Name

Condition Name for Olumiant
Intervention	Trials
Covid19	2
Corona Virus Infection	2
Mild Cognitive Impairment	1

Condition MeSH

Condition MeSH for Olumiant
Intervention	Trials
COVID-19	3
Pneumonia	2
Coronavirus Infections	2

Clinical Trial Locations for Olumiant

Trials by Country

Trials by Country for Olumiant
Location	Trials
United States	12
China	4
Italy	2
Denmark	1
Turkey	1

Trials by US State

Trials by US State for Olumiant
Location	Trials
North Carolina	1
Tennessee	1
Minnesota	1
Georgia	1
Connecticut	1

Clinical Trial Progress for Olumiant

Clinical Trial Phase

Clinical Trial Phase for Olumiant
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	2
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Olumiant
Clinical Trial Phase	Trials
Recruiting	7
Not yet recruiting	7
Active, not recruiting	1

Clinical Trial Sponsors for Olumiant

Sponsor Name

Sponsor Name for Olumiant
Sponsor	Trials
Eli Lilly and Company	2
Horus Pharma	1
China-Japan Friendship Hospital	1

Sponsor Type

Sponsor Type for Olumiant
Sponsor	Trials
Other	32
Industry	4